Catalyst Biosciences, Inc. (NASDAQ: CBIO)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Catalyst Biosciences, Inc. Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Catalyst Biosciences, Inc. Company Info
A biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics, a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system.
News & Analysis
A bad week for these two biotechs could be a good week for bargain shoppers.
Find out why good news elsewhere hurt one of these stocks.
The notable moves and news of the day.
These stocks sank like rocks.
Targacept revises its data for TC-6987 downward.
Are these three stocks set up for a large move?
This adjunct depression treatment is done.
These five stocks only made shorts some serious money last week.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.